News Sentiment

LTRN sentiment intelligence

Lantern Pharma Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 3.60 Week of 10 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-9.3% over one week, -7.2% over four weeks, trend active, and near fair-value range.

Latest direct headline Positive

New to The Street Show #761 to Broadcast Across Bloomberg U.S., Latin America and MENA, Featuring Sagtec Global, Virtuix, Lantern Pharma and YY Group

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction -9.3% Price reacting lower
Trend fit Trend active -7.2% over four weeks
Fair value -10.1% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 19
Neutral 35
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
Market source 8
TradingKey 5
Business Wire 4
TradingView 3
BioSpace 3
Investing.com 3
simplywall.st 3

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 19
Balance sheet 3
Analyst action 2
Capital return 2
Regulatory and legal 1
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-57 of 57
Stock Titan Direct company coverage

Lantern Pharma (NASDAQ: LTRN) raises $4.4M and plans withZeta.ai spinout

Lantern Pharma reported a Q1 2026 net loss of $3.33 million, a reduction from the previous year, with cash and equivalents totaling $6.3 million. Despite a recent $4.4 million equity raise, the company noted "substantial doubt" about its ability to continue as a going concern, an

Tone
Negative 39/100
Event
Balance sheet
Published
15 May 2026 19:40
Source
Stock Titan